The DOI matches its Crossref record.
SIRT1 – An Anti-Inflammatory Pathway at the Crossroads Between Metabolic Disease and Atherosclerosis
Abstract
Atherosclerosis is a chronic inflammatory disease that is based on the interaction between inflammatory cell subsets and specific cells in the arterial wall. SIRT1 deacetylates histone and non-histone proteins and has been implicated in protective effects of caloric restriction on lifespan and metabolic pathways in yeast, nematodes, and mice. In the vasculature of rodents, SIRT1 mediates vasodilatation through the release of endothelial nitric oxide synthase-derived nitric oxide and scavenges reactive oxygen species. Using a genetic loss-of-function approach, SIRT1 has been shown to interfere with crucial steps of endothelial activation and atherogenesis by suppressing NFκB signaling: Partial SIRT1 deletion in ApoE-/- mice prevented expression of endothelial adhesion molecules thereby hampering the extravasation of circulating monocytes. In monocyte-derived macrophages SIRT1 deletion reduced the expression of the scavenger receptor lectin-like oxidized low-density lipoprotein receptor 1 (Lox-1) resulting in reduced foam cell formation and atherosclerosis. Moreover, it was reported that SIRT1 regulates the activity of liver X-receptor, thereby promoting ABCA1-driven reverse cholesterol transport in plaque-resident macrophages slowing foam cell formation. Finally, SIRT1 suppressed the expression of endothelial tissue factor, and thus exerted anti-thrombotic properties during induced carotid thrombosis in mice. These findings indicate protective effects of SIRT1 in atherogenesis…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mounting evidence has demonstrated that intracellular activation of SIRT1 protects against atherosclerosis.30–33”
From Sirtuin-1 directly binds and deacetylates hepatic PCSK9 thereby promoting the inhibition of LDL receptor degradation (2025) · cites this paper as [32]
Citations
Cited by
Sorted by citations
Nutraceutical Activation of Sirt1: A Review
DiNicolantonio, J. J., McCarty, M. F., & O'Keefe, J. H. (2022) · Open Heart · doi:10.1136/openhrt-2022-002171 · Cited by 65
Velagapudi, S., Miranda, M. X., Adla, P., Kraler, S., Mohammed, S. A., Baki, S., Robert, J., Rohrer, L., Lee, H., Jang, H.-D., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf087 · Cited by 4
Metadata
- Authors
- Winnik, S., Stein, S., & M. Matter, C.
- Venue
- Current Vascular Pharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-10-01
- Volume
- 10
- Issue
- 6
- Pages
- 693-696
- ISSN
- 1570-1611
- Cited by
- 59
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: SIRT1 – An Anti-Inflammatory Pathway at the Crossroads Between Metabolic Disease and Atherosclerosis. https://app.cochat.ai/papers/10.2174/157016112803520756
- The paper
- Winnik, S., Stein, S., & M. Matter, C. (2012). SIRT1 – An Anti-Inflammatory Pathway at the Crossroads Between Metabolic Disease and Atherosclerosis. Current Vascular Pharmacology. https://doi.org/10.2174/157016112803520756